ITEM 7.01 REGULATION FD DISCLOSURE

On September 20, 2012, Chromadex Corporation (the "Company") issued a press release with respect to certain test results pertaining to the impact of pterostilbene on blood pressure and other metabolic parameters in adults that were announced on September 20, 2012 by the American Heart Association, the abstract of such results is attached hereto as Exhibit 99.1. A copy of the press release is attached hereto as Exhibit 99.2 and is incorporated herein by reference.

The information disclosed under this Item 7.01, including Exhibit 99.1 and Exhibit 99.2 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document pursuant to the Securities Act, except as expressly set forth in such filing.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits Exhibit No. Description Abstract of the Impact Of Pterostilbene On Blood Pressure and Other 99.1 Metabolic Parameters In Adults, dated September 20, 2012 99.2 Press Release

---